Oscar Health Shares Surge After Insider Buying

CEO Mark T. Bertolini purchased 1 million shares, boosting his stake in the company

Apr. 8, 2026 at 2:57pm

Got story updates? Submit your updates here. ›

Shares of Oscar Health, Inc. (NYSE:OSCR) jumped 11.8% on Wednesday after the company's CEO, Mark T. Bertolini, bought 1 million additional shares in a transaction worth $11.92 million. The purchase increased Bertolini's stake in Oscar Health to over 10 million shares, valued at $121.5 million.

Why it matters

Insider buying activity is often seen as a positive signal, as it suggests company leadership has confidence in the business's future prospects. Oscar Health's stock has been volatile since its public debut, and this sizable purchase by the CEO could help boost investor sentiment.

The details

Bertolini's purchase represents a 10.87% increase in his personal stake in Oscar Health. The company provides individual and family health insurance plans, as well as Medicare Advantage offerings, through a proprietary digital platform. Oscar Health has faced challenges, including reporting wider-than-expected losses in recent quarters, but the CEO's investment signals his belief in the company's long-term potential.

  • On Monday, April 6th, 2026, CEO Mark T. Bertolini purchased 1 million shares of Oscar Health stock.
  • Oscar Health's shares closed at $12.97 on the previous trading day.

The players

Oscar Health, Inc.

A technology-driven health insurance company headquartered in New York City that offers individual, family, and Medicare Advantage plans.

Mark T. Bertolini

The Chief Executive Officer of Oscar Health, who purchased 1 million additional shares in the company, increasing his personal stake to over 10 million shares.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching to see if Oscar Health's stock can maintain its momentum following the CEO's insider buying activity.

The takeaway

The sizable purchase by Oscar Health's CEO suggests he believes the company's long-term prospects justify the current stock price, which could help boost investor confidence in the face of the company's recent financial challenges.